Previous Pause Next
Home >> News Center >>
Enterprise & Industry
Pfizer Plans to Cut Spanish Workforce by 11%, Expansion Reports PDF Print E-mail
Friday, 23 September 2011 00:31

Pfizer Inc (PFE) plans to cut its workforce in Spain by 11 percent, or 220 employees, because of the financial crisis in Europe and Spanish regulatory measures to reduce pharmaceutical spending, Expansion reported.

Roche Halts Delivery To Greece Over Payments PDF Print E-mail
Thursday, 22 September 2011 00:42
For the second time since Greece began facing a fiscal crisis, a big drugmaker has stopped delivering drugs to the beleaguered nation. More specifically, Roche is no longer sending meds for cancer and other afflictions to state-owned hospitals that have not paid their bills and the drugmaker may do the same in other countries, such as Spain, Italy and Portugal, where bills are going unpaid.
Sangamo BioSciences, Inc.'s Blood-Cell Gene Therapy Fights HIV Without Drugs PDF Print E-mail
Thursday, 22 September 2011 00:34
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach for the treatment of HIV/AIDS, were discussed in two presentations at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The meeting is being held in Chicago from September 17-20, 2011.
FDA Approves Amgen's Prolia the Go-Ahead in Two Cancer Therapy-Induced Bone Loss Indications PDF Print E-mail
Wednesday, 21 September 2011 00:27
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.
Life Technologies Applauds Signing of Patent Reform Bill PDF Print E-mail
Tuesday, 20 September 2011 00:31
Life Technologies Corporation (NASDAQ: LIFE) applauds the signing by President Barack Obama of "The Leahy-Smith America Invents Act" (H.R. 1249). President Obama will sign the bill today at Thomas Jefferson High School for Science and Technology in Alexandria, Virginia.
GlaxoSmithKline , McLaren Strike Alliance to Turbocharge R&D; New Jobs to be Created PDF Print E-mail
Tuesday, 20 September 2011 00:27

GlaxoSmithKline has turned to the engineering expertise of Formula 1 racing team McLaren in an innovative alliance designed to transform its manufacturing, R&D and consumer health divisions.

Vertex Pharmaceuticals (MA) Gears Up Sales Force for CF Drug Launch, 150 Jobs Available Now, 500 by 2015 PDF Print E-mail
Monday, 19 September 2011 00:09
Biotech firm Vertex, fresh off the introduction of Incivek for hepatitis C, is busying itself with launch preparations once again. The firm said it's hiring across the company to support the anticipated debut of cystic fibrosis (CF) drug VX-770.


Lupin Pharmaceuticals, Inc. Announces Launch of Generic KEPPRA XR(R) Tablets PDF Print E-mail
Saturday, 17 September 2011 00:58
Lupin Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of UCB's KEPPRA XR tablets. Commercial shipment of the product has commenced.
Banking on Botox No Concern for Allergan Inc. CEO PDF Print E-mail
Saturday, 17 September 2011 00:36
Allergan Inc (AGN.N) is not worried about over-reliance on sales of its flagship Botox drug, the company's chief said, citing extensive safety data and supply reserves of the injectable medicine.
AEterna Zentaris Presents Positive Final Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at European Society of Gynecological Oncology Meeting in Milan, Italy PDF Print E-mail
Friday, 16 September 2011 00:29
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.
Orexigen Therapeutics, Inc. Surges After Revival of Obesity Drug Rejected by FDA Begins PDF Print E-mail
Friday, 23 September 2011 00:26
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced today that following a recent meeting with senior officials in FDA's Office of New Drugs (OND), the Company received written correspondence detailing OND's design requirements for a cardiovascular outcomes trial (CVOT) for Contrave® that would address the Complete Response Letter (CRL) received in January 2011.
Bristol-Myers Squibb Company's Once-Daily Hepatitis C Drug Works in Phase II Study PDF Print E-mail
Thursday, 22 September 2011 00:37
Bristol-Myers Squibb Company (NYSE:BMY - News) today announced results from a Phase II clinical trial of 48 treatment-naive genotype 1 hepatitis C infected patients in which treatment with BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa and ribavirin (pegIFNalfa/RBV) maintained undetectable viral load at 24 weeks post-treatment (SVR24) in 83% (60 mg), 83% (10 mg) and 42% (3 mg) of patients, compared with 25% of patients in the pegIFNalfa/RBV control group after 48 weeks of combination therapy.
Merck & Co., Inc. HIV Treatment Effective In Combination Study PDF Print E-mail
Wednesday, 21 September 2011 00:30
Merck (NYSE:MRK - News), known as MSD outside the United States and Canada, today announced results from the REALMRK clinical study showing that after 48 weeks of treatment in an open-label, single-arm, observational study, the integrase inhibitor ISENTRESS® (raltegravir) tablets in combination therapy demonstrated efficacy and tolerability, regardless of gender or race, in a diverse population of adult patients with HIV-1 infection similar to results from other Phase III studies.
Hematech, Inc. Cuts 18 Jobs to Cope With Parent Firm's Changing Needs PDF Print E-mail
Wednesday, 21 September 2011 00:22
A Sioux Falls-based biotechnology firm says it has laid off 18 employees in response to changing needs of its parent company.

Hematech CEO Eddie Sullivan tells the Argus Leader ( that the layoffs included researchers, technicians and support staff. 
Qualitest Pharmaceuticals Pharma Recalls Oral Contraceptives PDF Print E-mail
Tuesday, 20 September 2011 00:29
Qualitest Pharmaceuticals today issued a voluntary, nationwide, retail-level recall of multiple lots of oral contraceptives. The recall is being implemented because of a packaging error, where select blisters were rotated 180 degrees within the card, reversing the weekly tablet orientation and making the lot number and expiry date no longer visible.
GlaxoSmithKline (GSK) Anti-Nausea Drug Linked to Arrhthymias PDF Print E-mail
Monday, 19 September 2011 00:16
U.S. health regulators said they are reviewing the safety of GlaxoSmithKline's anti-nausea drug Zofran to ascertain whether there is a potential risk of abnormal heart rhythm.
Pfizer Inc. Cutting Hundreds of Jobs in Germany PDF Print E-mail
Monday, 19 September 2011 00:02

The world’s biggest pharmaceutical firm Pfizer is cutting more than 500 jobs in Germany – around one in eight of the work places in the country, according to insiders who have spoken to the Handelsblatt newspaper.

Pfizer Said to Delay Sales of Baby Formula Unit as It Explores Spinoff PDF Print E-mail
Saturday, 17 September 2011 00:55

Pfizer Inc. (PFE) is delaying a sale of its infant-nutrition business to give it more time to explore whether a tax-free spinoff will get more value for investors, said people with direct knowledge of the plans.

Daiichi Unit Warned By FDA Over Manufacturing PDF Print E-mail
Friday, 16 September 2011 00:34
Yet another unit of Daiichi Sankyo has elicited the wrath of the FDA. The agency issued a warning letter to its Luitpold Pharmaceuticals subsidiary for “significant” and repeated violations at a Long Island, New York, manufacturing plant.
Transcept Pharmaceuticals, Inc. Announces FDA Response to Proposal in Support of Intermezzo(R) New Drug Application PDF Print E-mail
Friday, 16 September 2011 00:18
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) received notice today from the U.S. Food and Drug Administration (FDA) that it generally agrees with Transcept proposals to address concerns raised by the FDA in its July 2011Intermezzo® Complete Response Letter.
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 7 of 127